A study compared the bleeding risks of the blood thinners rivaroxaban, apixaban, and warfarin for patients with blood clots or atrial fibrillation. Rivaroxaban was found to have a significantly higher risk of bleeding than apixaban and warfarin. The study involved over 10 years of patient data from Michigan’s Anticoagulation Quality Improvement Initiative registry. Researchers also noted that of the three medications, apixaban had a lower mortality rate than rivaroxaban and warfarin, and a higher rate of blood clots than warfarin. These findings may have implications for the selection of anticoagulants for patients and further research is needed.
Source link
Common oral anticoagulant rivaroxaban linked to highest risk of bleeding complications
